Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Hudson

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Clinical Therapeutics|July 1, 1996
Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerR Sharifi, R C Bruskewitz, M C Gittleman, et al.
The Journal of Antibiotics|March 1, 1982
Microbiological conversion of 4-epi-cetocycline to 2-decarboxamido-2-acetyl-4-dedimethyl-9-methyltetracyclineR J Theriault, L Guagliardi, P B Hudson, et al.
The Journal of Urology|December 22, 1999
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety studyC G Roehrborn, J McConnell, J Bonilla, et al.
Urology|April 10, 1999
Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study GroupP B Hudson, R Boake, J Trachtenberg, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Clinical Therapeutics|July 1, 1996
Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerR Sharifi, R C Bruskewitz, M C Gittleman, et al.
The Journal of Antibiotics|March 1, 1982
Microbiological conversion of 4-epi-cetocycline to 2-decarboxamido-2-acetyl-4-dedimethyl-9-methyltetracyclineR J Theriault, L Guagliardi, P B Hudson, et al.
The Journal of Urology|December 22, 1999
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety studyC G Roehrborn, J McConnell, J Bonilla, et al.
Urology|April 10, 1999
Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study GroupP B Hudson, R Boake, J Trachtenberg, et al.
Pageof 3